Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludarabine
Drug ID BADD_D00914
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status Not Available
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D07966
MeSH ID C024352
PubChem ID 657237
TTD Drug ID D0F2XQ
NDC Product Code Not Available
Synonyms fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine
Chemical Information
Molecular Formula C10H12FN5O4
CAS Registry Number 21679-14-1
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.0020.000533%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.006533%Not Available
Malaise08.01.01.003--
Meningitis aseptic17.06.03.002; 11.01.03.0020.000533%Not Available
Metabolic acidosis14.01.01.003--Not Available
Metastases to liver09.04.02.004; 16.22.02.0010.000208%Not Available
Mucosal inflammation08.01.06.0020.000139%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000799%
Myalgia15.05.02.001--
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.001251%
Myeloid leukaemia01.10.08.001; 16.01.08.0010.000533%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neoplasm16.16.02.0010.000347%Not Available
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.003463%Not Available
Neutropenia01.02.03.0040.001865%Not Available
Neutrophil count decreased13.01.06.010--
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Opportunistic infection11.01.08.007--Not Available
Optic neuritis10.04.10.002; 06.04.08.002; 17.04.05.001--Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pancreatitis07.18.01.0010.001066%
Pancytopenia01.03.03.0030.000417%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages